Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases.

ABSTRACT: Precise hepatocellular carcinoma (HCC) risk prediction will play increasingly important roles with the contemporary HCC etiologies, that is, non-alcoholic fatty liver disease and resolved hepatitis C virus infection. Because the HCC incidence rate in this emerging patient population is relatively low (~1% per year), identification of a subset of patients at the highest risk is critical to concentrate the effort and resources of regular HCC screening to those who most need it. Omics profiling has been derived using several candidate HCC risk biomarkers, which could refine HCC screening by enabling individual risk-based personalized or risk-stratified patient management. Various types of biomolecules have been explored as sources of information to predict HCC risk at various time horizons. G

SUBMITTER: Fujiwara N 

PROVIDER: S-EPMC8318383 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature